Sophie Dessureault, MD, PhD

Where You Are:
Sophie Dessureault, MD, PhD

Associate Member

"Dr. Dessureault continues working on the next generation of cancer vaccines that will focus on reversing tumor-induced immune suppression."

Office  (813) 745-3636

Education And Training
  • Fellow, H. Lee Moffitt Cancer Center, University of South Florida, 2001 - Surgical Oncology
  • PhD, University of Toronto, Toronto, Ontario, 1999
  • Resident, University of Toronto, Toronto, Ontario, 1999 - Surgery
  • Intern, St. Michael's Hospital, Toronto, Ontario, 1991
  • MD, Dalhousie University, Halifax, Nova Scotia, 1990
  • BSc, Dalhousie University, Halifax, Nova Scotia, 1986 - Biology

Dr. Dessureault is collaborating with other researchers to test various cancer vaccines in clinical trials.

  • Koskan AM, Thomas-Purcell KB, Yu D, Quinn GP, Dessureault S, Shibata D, Jacobsen PB, Gwede CK. Discussion of First-Degree Relatives' Colorectal Cancer Risk: Survivors' Perspectives. Health Commun. 2014 Sep;29(8):782-790. Pubmedid: 24229427.
  • Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience. Ann Surg Oncol. 2014 May;21(5):1480-1486. Pubmedid: 24158467.
  • Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, Bulusu A, Annechiarico RP, Chadaram V, Clay TM, Lyerly HK. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg. 2013 Dec;258(6):879-886. Pubmedid: 23657083. Pmcid: PMC3812363.
  • Kiluk JV, Dessureault S, Quinn G. Teaching medical students how to break bad news with standardized patients. J Cancer Educ. 2012 Jun;27(2):277-280. Pubmedid: 22314793.
  • Kiluk JV, Ly QP, Meade T, Ramos D, Reintgen DS, Dessureault S, Davis M, Shamehdi C, Cox CE. Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up. Ann Surg Oncol. 2011 Dec;18 Suppl 3:339-342. Pubmedid: 19777181.
  • Manne S, Jacobsen PB, Ming ME, Winkel G, Dessureault S, Lessin SR. Tailored versus generic interventions for skin cancer risk reduction for family members of melanoma patients. Health Psychol. 2010 Nov;29(6):583-593. Pubmedid: 21090893. Pmcid: PMC3058834.
  • Bui MM, Draper NL, Dessureault S, Nasir NA, Cooper H, Nasir A, Coppola D. Colonic angiolymphoid hyperplasia with eosinophilia masquerading as malignancy: a case report and review of the literature. Clin Colorectal Cancer. 2010 Jul;9(3):179-182. Pubmedid: 20643624.
  • Desai S, Maurin M, Smith MA, Bolick SC, Dessureault S, Tao J, Sotomayor E, Wright KL. PRDM1 is required for mantle cell lymphoma response to bortezomib. Mol Cancer Res. 2010 Jun;8(6):907-918. Pubmedid: 20530581. Pmcid: PMC2891394.
  • Giglia JL, Antonia SJ, Berk LB, Bruno S, Dessureault S, Finkelstein SE. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control. 2010 Apr;17(2):120-129. Pubmedid: 20404795.
  • Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, Sotomayor E, Tao J, Cheng JQ. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010 Apr;115(13):2630-2639. Pubmedid: 20086245. Pmcid: PMC2852365.
  • Kiluk JV, Ly QP, Santillan AA, Meade T, Ramos D, Reintgen DS, Dessureault S, Davis M, Shamehdi C, Cox CE. Erratum to: Axillary Recurrence Rate Following Negative Sentinel Node Biopsy for Invasive Breast Cancer: Long-Term Follow-Up. Ann Surg Oncol. 2010 Feb;17(2):552-557. Pubmedid: 19957043.
  • Lwin T, Crespo LA, Wu A, Dessureault S, Shu HB, Moscinski LC, Sotomayor E, Dalton WS, Tao J. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia. 2009 Jan;23(1):170-177. Pubmedid: 18843286.
  • Moller M, Lewis J, Dessureault S, Zager J. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia. 2008 May;24(3):275-289. Pubmedid: 18393005.
  • Lwin T, Hazlehurst LA, Dessureault S, Lai R, Bai W, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood. 2007 Sep;110(5):1631-1638. Pubmedid: 17502456. Pmcid: PMC1975846.
  • Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia. 2007 Jul;21(7):1521-1531. Pubmedid: 17476277.
  • Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia S. A phase-I Trial Using a Universal GM-CSF-producing and CD40L-expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-based Vaccines for Cancer Patients with Stage IV disease. Ann Surg Oncol. 2007 Feb;14(2):869-884. Pubmedid: 17103257.
  • Thompson P, Dessureault S. Tumor cell vaccines. Adv Exp Med Biol. 2007;601:345-355. Pubmedid: 17713023.
  • Dessureault S. Commentary: Evidence-based principles applied to the management of colorectal cancer. Cancer Treat Rev. 2006 Nov;32(7):581-581. Pubmedid: 16884857.
  • Cox C, White L, Allred N, Meyers M, Dickson D, Dupont E, Cantor A, Ly Q, Dessureault S, King J, Nicosia S, Vrcel V, Diaz N. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy. Ann Surg Oncol. 2006 May;13(5):708-711. Pubmedid: 16538416.
  • Azzarello L, Dessureault S, Jacobsen P. Sun-Protective Behavior among Individuals with a Family History of Melanoma. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):142-145. Pubmedid: 16434600.
  • Dessureault S, Alsarraj M, McCarthy S, Hunter T, Noyes D, Lee D, Harkins J, Seigne J, Jennings R, Antonia S. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. J Surg Res. 2005 May;125(2):173-181. Pubmedid: 15854671.
  • Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002 Sep;101(2):151-155. Pubmedid: 12209992.
  • Kim C, Dessureault S, Gabrilovich D, Reintgen D, Slingluff C. Immunotherapy for melanoma. Cancer Control. 2002;9(1):22-30. Pubmedid: 11907463.
  • Dessureault S, Coppola D, Weitzner M, Powers P, Karl R. Barrett's esophagus and squamous cell carcinoma in a patient with psychogenic vomiting. Int J Gastrointest Cancer. 2002;32(1):57-61. Pubmedid: 12630772.
  • Dessureault S, Soong S, Ross M, Thompson J, Kirkwood J, Gershenwald J, Coit D, McMasters K, Balch C, Reintgen D. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001;8(10):766-770. Pubmedid: 11776489.
  • Stewart A, Lassam N, Quirt I, Bailey D, Rotstein L, Krajden M, Dessureault S, Gallinger S, Cappe D, Wan Y, Addison C, Moen R, Gauldie J, Graham F. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther. 1999;6:350-363. Pubmedid: 10435085.
  • Dessureault S, Graham F, Gallinger S. Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells. Cancer Gene Therapy. 1999;6(3):195-208. Pubmedid: 10359205.
  • Prince H, Dessureault S, Gallinger S, Krajden M, Sutherland D, Addison C, Zhang Y, Graham F, Stewart S. Efficient adenoviral-mediated gene expression in malignant human plasma cells: relative lymphoid cell resistance. Exp Hematol. 1998;26:27-36. Pubmedid: 9430511.
  • Dessureault S. Ongoing Studies with GM. Cd40L Bystander-Based Vaccines. nn S rg ; (2). Pubmedid: 18231837.
  • Lewis J, Zager J, Yu D, Pelaez D, Riker A, Dessureault S, Cruse C, Reintgen D, Puleo C, Sondak V. Full-Thickness Grafts Procured from Skin Overlying the Sentinel Lymph Node Basin; Reconstruction of Primary Cutaneous Malignancy Excision Defects. Ann Surg Oncol. 2008 Jun;15(6):1733-1740. Pubmedid: 18379848.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions